Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent...
Saved in:
Published in | Nature immunology Vol. 22; no. 12; pp. 1503 - 1514 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.12.2021
Nature Publishing Group Nature Research, Springer Nature |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!